Reactive granulomatous dermatitis arising in the setting of interleukin-17 inhibition successfully treated with tofacitinib

Reactive granulomatous dermatitis (RGD) encompasses a spectrum of cutaneous granulomatous disorders. Classically, these eruptions had been divided into interstitial granulomatous dermatitis, interstitial granulomatous drug reaction, and palisaded neutrophilic and granulomatous dermatitis. However, more recently RGD, which encompasses these 3 diagnoses, which may overlap with 1 another, has become the preferred nomenclature. RGD is most commonly associated with inflammatory arthritis and systemic lupus erythematosus, as well as the use of certain medications, including tumor necrosis factor inhibitors.